{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:54:06Z","timestamp":1791820446266,"version":"4.3.4"},"reference-count":60,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>The management of Sj\u00f6gren's disease is challenging because of several factors. Indeed, the clinical presentations are heterogeneous, and one must be able to identify prognostic markers to adapt the follow\u2010up. In addition, there is no validated treatment. Nevertheless, international experts have been working for several years to establish recommendations to guide management. Since research in this field is extremely active, we anticipate the development of effective treatments for our patients in the near future.<\/jats:p>","DOI":"10.1002\/art.42612","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T16:03:35Z","timestamp":1685030615000},"page":"2078-2087","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Expert Perspective: Challenges in Sj\u00f6gren's Disease"],"prefix":"10.1002","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-0733","authenticated-orcid":false,"given":"Gaetane","family":"Nocturne","sequence":"first","affiliation":[{"name":"Department of Rheumatology Universit\u00e9 Paris\u2010Saclay, INSERM UMR1184, Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":false,"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Universit\u00e9 Paris\u2010Saclay, INSERM UMR1184, Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41676"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206860"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39859"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204634"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210448"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215024"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001503"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110619"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143743"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209952"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002955"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059868"},{"key":"e_1_2_8_15_1","unstructured":"Evolution of disease activity over a 5\u2010year period in the 395 patients with primary Sj\u00f6Gren's syndrome of the ASSESS prospective cohort. ACR Meeting Abstracts. URL:https:\/\/acrabstracts.org\/abstract\/evolution\u2010of\u2010disease\u2010activity\u2010over\u2010a\u20105\u2010year\u2010period\u2010in\u2010the\u2010395\u2010patients\u2010with\u2010primary\u2010sjogrens\u2010syndrome\u2010of\u2010the\u2010assess\u2010prospective\u2010cohort\/."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9553-3"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874312901409010036"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001033"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216222"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002234"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216114"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.2.174"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.09.013"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048336"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.04.011"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7682"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex490"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30057-6"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa257"},{"key":"e_1_2_8_30_1","unstructured":"NocturneG PontariniE BombardieriM et al.Lymphomas complicating primary Sj\u00f6gren's syndrome: from autoimmunity to lymphoma. PMID: 30838413."},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13192"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab949"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40829"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa441"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.1.97"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30686-0"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.010"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.6994"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221604"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)00021-0"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15120"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61040-4"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev200"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0011-2016"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00359-9"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181579781"},{"key":"e_1_2_8_47_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000179","article-title":"Epidemiology of neurological manifestations in Sj\u00f6gren's syndrome: data from the French ASSESS Cohort","volume":"2","author":"Alegria GC","year":"2016","journal-title":"RMD Open"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci9040085"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1085"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40093"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30135-3"},{"key":"e_1_2_8_52_1","unstructured":"A phase 2a study of MEDI5872 (AMG557) a fully human anti\u2010ICOS ligand monoclonal antibody in patients with primary Sj\u00f6gren's syndrome [abstract]. URL:https:\/\/acrabstracts.org\/abstract\/a\u2010phase\u20102a\u2010study\u2010of\u2010medi5872\u2010amg557\u2010a\u2010fully\u2010human\u2010anti\u2010icos\u2010ligand\u2010monoclonal\u2010antibody\u2010in\u2010patients\u2010with\u2010primary\u2010sjogrens\u2010syndrome\/."},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218467"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214720"},{"key":"e_1_2_8_55_1","article-title":"Randomized, double\u2010blind, placebo\u2010controlled phase III study to assess the efficacy and safety of abatacept in patients with primary Sj\u00f6gren's syndrome (ASAP III Study = Abatacept Sj\u00f6gren Active Patients Phase III Study)","author":"Bootsma DH","year":"2019","journal-title":"ClinicalTrials.gov"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218599"},{"key":"e_1_2_8_57_1","article-title":"A randomized, double\u2010blind, placebo\u2010controlled, proof\u2010of\u2010concept study to evaluate the efficacy of UCB5857 over 12\u2009weeks in subjects with primary Sj\u00f6gren's syndrome","author":"UCB Celltech","year":"2020","journal-title":"ClinicalTrials.gov"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163030"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac167"},{"key":"e_1_2_8_60_1","unstructured":"Remibrutinib (LOU064) in Sj\u00f6gren's Syndrome: Safety and Efficacy Results from a 24\u2010Week Placebo\u2010controlled Proof\u2010of\u2010Concept Study [abstract]. December2022. URL:https:\/\/acrabstracts.org\/abstract\/remibrutinib\u2010lou064\u2010in\u2010sjogrens\u2010syndrome\u2010safety\u2010and\u2010efficacy\u2010results\u2010from\u2010a\u201024\u2010week\u2010placebo\u2010controlled\u2010proof\u2010of\u2010concept\u2010study\/."},{"key":"e_1_2_8_61_1","unstructured":"Horizon Therapeutics plc 2022 Horizon Therapeutics plc announces Phase 2 trial evaluating dazodalibep for the treatment of Sj\u00f6gren's syndrome meets primary endpoint"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:33:06Z","timestamp":1759951986000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/art.42612"],"URL":"https:\/\/doi.org\/10.1002\/art.42612","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"2023-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}